

22<sup>nd</sup> January, 2020

(1) BSE Ltd  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

Dear Sir/Madam,

**Sub: Update on USFDA inspection at Cipla's manufacturing facility in Goa**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company wishes to inform you that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI).

The Company does not believe that this will have any material impact on the US business at this stage. The Company has a strong track record of maintaining the highest standard of compliance and will work closely with the agency to comprehensively address the observations received.

Kindly take the above information on record.

Thanking you,

Yours faithfully,  
For Cipla Limited



Rajendra Chopra  
Company Secretary



Prepared by: Mandar Kurghode